Non-Muscle Invasive Bladder Cancer (NMIBC) Market

The Non-Muscle Invasive Bladder Cancer (NMIBC) Market is anticipated to surge with a CAGR of 8% during the study period 2017-2030. There are several unmet needs in the NMIBC market, and no approved therapy to offer relief to the patients.

To address the unmet needs, several pharma and biotech companies were, and still are trying hard, with novel promising agents including gene therapies and fusion proteins in their pipeline.

The NMIBC Market is going to experience a significant boost in the coming years owing to several factors ranging from the strong pipeline to an increase in prevalence.

For more details, visit: https://www.delveinsight.com/blog/nmibc-market-drivers-and-barriers/